{
  "docId": "019de073-f22f-749b-aa66-140061a622d8",
  "docSlug": "bfa8f27558bcf20e1dab95d83263e96b",
  "documentTitle": "Berkeley Lights | Investor Day Presentation Deck | 91 slides",
  "authorId": "berkeley-lights",
  "authorName": "Berkeley Lights",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 59,
  "pageCount": 91,
  "prevPage": 58,
  "nextPage": 60,
  "slideType": "scenario_table",
  "function": "quantify_opportunity",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Uses a 'multiplication' visual metaphor (Patient volume x COGS per dose = COGS reduction) to illustrate value.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f22f-749b-aa66-140061a622d8/59",
  "deckHref": "/decks/019de073-f22f-749b-aa66-140061a622d8",
  "deckJsonHref": "/decks/019de073-f22f-749b-aa66-140061a622d8.json",
  "deckAnchorHref": "/decks/019de073-f22f-749b-aa66-140061a622d8#slide-59",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.12,
        "x": 0.42,
        "y": 0.75
      },
      "kind": "chart",
      "text": "1000L batch yield comparison",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "035610e4-b288-44dc-b2f7-2d80b4928d7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.12,
        "x": 0.42,
        "y": 0.38
      },
      "kind": "chart",
      "text": "COGS per dose comparison between Stable and Transient",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "285727d2-3e8b-4c7f-b1eb-1236b04daefd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "COGS reduction in Phase 1 trial batches and commercial batches",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "133c89c2-abb7-44f6-9c7c-578740e58693",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.75,
        "y": 0.08
      },
      "kind": "paragraph",
      "text": "Development of stable PCL's will be required to support future AAV launches in high-population indications requiring systemic doses.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16884276-b842-4ea0-af32-914551813767",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "Benchmark based on Phase 1 trials of non-rare diseases; Based on non-rare disease with wet AMD; Systemic AAV dose of 3x10^15 vg.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6f66d9c-c27b-4883-9b67-72f37a45b768",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "BLI technology can enable up to 70% COGS reduction for pipeline AAVs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7b1dc2c-6473-408b-bf3b-9b5c709f3ee4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "2d9a51fe-2718-4ad7-a77c-c86a83bc0796",
      "evidence": "Shows the transition from current (Transient) to future (Stable) state with associated cost benefits.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 80,
      "from": 45,
      "beatId": "0e318181-28dc-401d-b762-c3ba1b0a4abe",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents Berkeley Lights' technology and growth strategy as a solution to the presented problems",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 59,
      "from": 51,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5881ba67-4f39-4100-b1e0-beb09a566b20",
      "evidence": "The document presents the potential benefits of Berkeley Lights' technology in reducing costs and improving efficiency",
      "position": 0,
      "objective": "Highlight the cost of inaction in gene therapy manufacturing",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}